Make your money go further for just 25p per day

IS Pharma (LON:ISPH) snaps up the rights to Episil

04/03/2010 · IS Pharma (ISPH) 

Comments Email Print
Share
The international speciality pharmaceutical company is on the acquisition trail again!

The Group has announced the acquisition for €1.75 million and royalties of the exclusive rights for Episil, an oncology supportive care product developed by Camurus AB (‘Camurus’), a privately owned Swedish life science company.

Episil is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.  Episil creates a strongly bioadhesive FluidCrystal® film that protects sensitive and…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on IS Pharma

IS Pharma plc – placing at a premium gives confidence and we get a dividend as well

06/10/2010 · Company Insights
The speciality pharmaceutical company has announced that it has raised £3.6m at 77p per share with…

IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme

02/06/2010 · Company Insights
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology…

More Company Insights

Strong growth | Moving on | Big warning

20/12/2024 · Elixirr International · IntegraFin Holdings · Sanderson Design Group · Shoe Zone · Zotefoams

Bonkers Bargains: another positive update

20/12/2024 · Time Finance

Insolvency solvency | Family fortunes | US delays

17/12/2024 · FRP Advisory Group · Goodwin PLC · Tristel

More on IS Pharma

IS Pharma plc – placing at a premium gives confidence and we get a dividend as well
IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme
IS Pharma (LON:ISPH)
IS Pharma (LON:ISPH) snaps up the rights to Episil

More Company Insights

Strong growth | Moving on | Big warning
Bonkers Bargains: another positive update
Insolvency solvency | Family fortunes | US delays

Search for AIM companies qualifying for relief from Inheritance Tax!

Use our unique screening tool to identify Inheritance Tax planning AIM companies

This search will take you to the separate AIMsearch web site which requires a different user name and password to this Investor's Champion site.
Investor’s Champion, making your money go further.

Sign-up to our free email updates

SIGN UP

ABOUT INVESTORS CHAMPION

Investor's Champion offers objective, incisive and forthright comment on quoted companies and personal finance. Our content addresses what we believe are the key issues in helping make your money go further.

Investor's Champion is a registered trade mark of Investors Champion Ltd. Investor's Champion Limited is a company registered in England and Wales under number 03577867 whose registered office is at c/o Cox Costello & Horne, Batchworth Lock House, 99 Church Street, Rickmansworth, WD3 1JJ.

All rights reserved. © 2007 - 2024